AbbVie Inc. (ABBV) exhibits 70.2% gross margins and 29.0% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 33.3x enterprise multiple and 4.8% implied options volatility.
Sustained 70.2% gross profitability converts into 24.6% operating margin and 29.0% ROIC, outpacing sector cost of capital.
ROIC: 29.0% // GM: 70.2%YoY revenue trajectory of +8.6% paired with 3.47% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +8.6% // FCF YLD: 3.47%Altman Z-Score of 5.33 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 5.33 // F-SCORE: 7/9Trading at 121.6x trailing P/E (113.1x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 121.6x // EV/EBITDA: 33.3xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $294.89 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 6.9% net margins.
NET MARGIN: 6.9% // D/E: 0.85x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for ABBV & activate live FRED threshold breach alerts.